您当前的位置：
首页 >
文章列表页 >
New Options for Second-Line Treatment of Pediatric Primary Immune Thrombocytopenia in Children: Eltrombopag and Romiplostim
更新时间：2023-11-08
|

    • New Options for Second-Line Treatment of Pediatric Primary Immune Thrombocytopenia in Children: Eltrombopag and Romiplostim

    • Vol. 29, Issue 11, Pages: 56-60(2023)
    • 作者机构：

      1. 淄博市中西医结合医院,山东,淄博,255026

      2. 齐齐哈尔医学院,黑龙江齐齐 哈尔,161006

    • DOI：10.13407/j.cnki.jpp.1672-108X.2023.11.016    

      CLC：

    • Published：2023，

      Published Online：10 November 2023，

    扫 描 看 全 文

  • Liu Feng, Fang Hongying, Xie Ran, et al. New Options for Second-Line Treatment of Pediatric Primary Immune Thrombocytopenia in Children: Eltrombopag and Romiplostim. [J]. 29(11):56-60(2023) DOI： 10.13407/j.cnki.jpp.1672-108X.2023.11.016.

  •  
  •  
查看原文

0

Views

12

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0